Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Systemic Mastocytosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for mKIT (mutant KIT) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | mKIT ECD-Fc / Mutant Kinase Domain Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View mKIT Products |
| Gene Delivery | mKIT Promise-ORF / Lentivirus Full-length ORF for stable cell lines (e.g., Ba/F3 mutant models). |
View mKIT Products |
| Benchmark Ab | Anti-KIT (Sequence of Clinical Benchmarks) Recombinant positive control. |
View mKIT Products |
| Validator | mKIT siRNA Set For knockdown verification and specificity checks. |
View mKIT Products |
| Related Target A | PDGFRA Synergistic pathway and mutually exclusive driver in GIST. |
View PDGFRA Products |
| Related Target B | FLT3 Structural homolog; critical for selectivity counter-screening. |
View FLT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. WT Selectivity Profiling | Comprehensive mutant panel (D816V, V654A, T670I, etc.) available with >95% purity and verified theoretical MW. |
| Cell-Based Resistance Modeling | Premade Lentivirus for stable expression of specific mKIT variants in Ba/F3 or HEK293 cells. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives in Screening | Validated siRNA included for target-specific knockdown verification. |
Live mKIT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for mKIT therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective, mutation-specific Tyrosine Kinase Inhibitors (TKIs) and targeted protein degraders (PROTACs). As first-generation therapies reach the clinic and resistance inevitably emerges (e.g., gatekeeper and activation loop mutations), the next wave of R&D is targeting broad-spectrum conformational control, mutant-selective ADCs, and bispecific antibodies to bypass traditional ATP-binding site resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen TKI | Blueprint Medicines, Deciphera | GIST, Systemic Mastocytosis | Selectivity Assay (Need high-purity Mutant vs WT Proteins) |
| ADC | Celldex, Loxo Oncology | KIT-positive Solid Tumors | Internalization Assay (Need HEK293 Expressed ECD-Fc) |
| PROTAC / Degrader | Kymera, Nurix | Refractory GIST | Degradation Assays (Need specific mutant Lentivirus cell lines) |
| Monoclonal Antibody | Various Biopharma | Allergic Diseases / Mast Cell Depletion | Epitope Mapping (Need Sequence Verified ECD variants) |